Definium Therapeutics, Inc. Common Shares
IPODefinium Therapeutics (Formerly MindMed) | Psychedelic Medicine
- Headquarters
- New York City, New York
- Employees
- 11–50
- Founded
- 2019
- Business Model
- B2B
- Website
- definiumtx.com
- Total Funding
- $371.0M
- Last Round
- $225.0M Corporate RoundAug 2023
- Rounds
- 4
- Type
- Public
About
Definium Therapeutics (formerly MindMed, founded in 2019) is a clinical-stage biopharmaceutical company headquartered in New York developing psychedelic-inspired medicines for psychiatric and neurological disorders. Its lead candidate, DT120 ODT, has received FDA Breakthrough Therapy Designation for generalized anxiety disorder and is in Phase 3 trials for both GAD and major depressive disorder. The company rebranded from MindMed to Definium Therapeutics in January 2026.
Tech & App Stack
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingSign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Investors
Sign up to view investors
Create a free account to see which investors have funded this company.
Create Free AccountSimilar Companies
Late-stage biopharma using single-molecule tracking, AI, and engineering to discover and develop ...
World-leading Canadian cannabis company cultivating and selling medicinal and recreational cannab...
Biopharmaceutical services company
Specialty pharmaceutical company
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...